Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE W HYDRALAZINE versus NAQUA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE W HYDRALAZINE versus NAQUA.
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE vs NAQUA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Hydralazine directly relaxes arteriolar smooth muscle via mechanisms involving nitric oxide, leading to vasodilation.
Inhibition of sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
Oral: hydrochlorothiazide 25-50 mg plus hydralazine 25-100 mg, twice daily; maximum hydralazine 300 mg/day.
Oral: 5-10 mg once daily, preferably in the morning. Maximum dose 20 mg/day.
None Documented
None Documented
Hydrochlorothiazide: 6-15 hours (terminal, prolonged in renal impairment); Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); clinical context: slow acetylators have higher risk of lupus-like reactions.
Terminal elimination half-life is 6-12 hours; prolonged in renal impairment (up to 20-30 hours) or heart failure due to reduced renal perfusion.
Hydrochlorothiazide: ~70% renal (unchanged), 30% metabolized with metabolites excreted renally; Hydralazine: 80-90% renal (metabolites), <10% unchanged, some biliary/fecal.
Primarily renal elimination; approximately 60-80% excreted unchanged in urine via tubular secretion; minor biliary/fecal excretion (<10%).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic